摘要
目的比较卡培他滨与替吉奥治疗晚期大肠癌的临床疗效。方法106例晚期大肠癌患者按数字表法随机分为卡培他滨组(52例)和替吉奥组(54例),观察比较两组临床效果和化疗不良反应。结果化疗1个疗程后,卡培他滨组完全缓解3例、部分缓解19例、病情稳定15例、病情进展15例、有效率42.3%、病情控制率71.2%,替吉奥组分别为5例、21例、19例、9例、48.1%、83.3%,两组有效率及疾病控制率差异均无统计学意义(P〉0.05)。两组化疗不良反应发生率和生存时间差异均无统计学意义(均P〉0.05)。结论卡培他滨与替吉奥治疗晚期大肠癌同样安全、有效。
Objective To test comparative effect of capecitabine and S-1 (Tegafur/gimeracil/oteracil)on advanced colorectal eancer. Methods 106 cases of advanced colorectal cancer in our hospital ontology were eoUeet- ed and randomly divided into 2 groups : capecitabine group ( 52 cases) and S-1 group ( 54 cases). The chemotherapy effect and adverse effect of 2 groups were collected. Results After one treatment period,3 cases of complete remis- sion, 19 cases of partial remission, 15 eases of stable disease, 15 cases of disease progression,efficient rate of 42.3% and control rate of 71.2% were observed in eapeeitabine group. 5 eases of complete remission,21eases of partial re- mission,19 cases of stable disease,9 cases of disease progression and efficient rate of 48.1% and control rate of 83.3% were observed in S-1 group. There were no significant differenees in efficient rate, control rate adverse effect rate and survival time between 2 groups ( P 〉 0.05 ). Conclusion Capeeitabine and S-1 are both safe and effective in treatment of advanced coloreetal cancer.
出处
《中国基层医药》
CAS
2013年第6期826-827,共2页
Chinese Journal of Primary Medicine and Pharmacy
关键词
结直肠肿瘤
卡培他滨
替吉奥
Colorectal neoplasms
Capecitabine
Gimeracil and Oteracil